IL268458A - Inhalable nicotine formulations, and methods of making and using thereof - Google Patents

Inhalable nicotine formulations, and methods of making and using thereof

Info

Publication number
IL268458A
IL268458A IL268458A IL26845819A IL268458A IL 268458 A IL268458 A IL 268458A IL 268458 A IL268458 A IL 268458A IL 26845819 A IL26845819 A IL 26845819A IL 268458 A IL268458 A IL 268458A
Authority
IL
Israel
Prior art keywords
making
methods
nicotine formulations
inhalable nicotine
inhalable
Prior art date
Application number
IL268458A
Other languages
Hebrew (he)
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/452,133 external-priority patent/US10149844B2/en
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of IL268458A publication Critical patent/IL268458A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL268458A 2017-03-07 2019-08-04 Inhalable nicotine formulations, and methods of making and using thereof IL268458A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/452,133 US10149844B2 (en) 2015-09-16 2017-03-07 Inhalable nicotine formulations, and methods of making and using thereof
PCT/IB2018/051482 WO2018163085A1 (en) 2017-03-07 2018-03-07 Inhalable nicotine formulations, and methods of making and using thereof

Publications (1)

Publication Number Publication Date
IL268458A true IL268458A (en) 2019-09-26

Family

ID=61731727

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268458A IL268458A (en) 2017-03-07 2019-08-04 Inhalable nicotine formulations, and methods of making and using thereof

Country Status (9)

Country Link
EP (1) EP3592352A1 (en)
JP (1) JP2020510002A (en)
KR (1) KR20190126772A (en)
CN (1) CN110300588A (en)
CA (1) CA3048677A1 (en)
IL (1) IL268458A (en)
MX (1) MX2019010263A (en)
RU (1) RU2770039C2 (en)
WO (1) WO2018163085A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4057845T3 (en) * 2019-11-14 2024-03-25 Philip Morris Products S.A. Improved tobacco flavoured dry powder formulation
MX2023002465A (en) * 2020-09-03 2023-03-23 Philip Morris Products Sa Freeze dried low hygroscopicity active powder compositions.
CN112841709B (en) * 2021-01-20 2022-11-25 深圳市艾普生物科技有限公司 Preparation method and application of nicotine salt
CN113880802A (en) * 2021-11-09 2022-01-04 深圳萨特瓦生物科技有限公司 Tartaric acid-nicotine salt, preparation method and application thereof, and preparation method of anhydrous tartaric acid crystal
WO2024091005A1 (en) * 2022-10-27 2024-05-02 주식회사 케이티앤지 Dry powder inhaler stick containing cough suppressant and dry powder inhaler comprising same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145819T1 (en) * 1992-03-10 1996-12-15 Fisons Plc INHALABLE MEDICINAL PRODUCTS
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1309312A2 (en) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
WO2003024396A2 (en) * 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
ITMI20012174A1 (en) * 2001-10-18 2003-04-18 Univ Parma POWDER FOR NASAL DRUG ADMINISTRATION
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (en) * 2005-10-21 2007-04-22 Eratech S R L INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US7832397B2 (en) * 2005-12-28 2010-11-16 Philip Morris Usa Inc. Aerosol powder delivery device
WO2008069972A2 (en) * 2006-12-01 2008-06-12 Aradigm Corporation Systems for effecting cessation of tobacco use
US20140294969A1 (en) * 2011-08-01 2014-10-02 Monash University Method and formulation for inhalation
JP6672258B2 (en) * 2014-04-08 2020-03-25 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム Nicotine preparation and method for producing the same
FR3035826B1 (en) * 2015-05-07 2018-11-16 Saint-Gobain Glass France VEHICLE GLAZING COMPRISING A PLATINUM FOR FASTENING MULTIPLE ACCESSORIES, PLATINUM AND FIXING METHOD.
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
CN105770862B (en) * 2016-04-22 2022-01-11 北京三元基因药业股份有限公司 Dry powder inhalant of interferon
MX2018015119A (en) * 2016-06-30 2019-04-15 Philip Morris Products Sa Nicotine particles.

Also Published As

Publication number Publication date
CN110300588A (en) 2019-10-01
JP2020510002A (en) 2020-04-02
KR20190126772A (en) 2019-11-12
RU2019128062A3 (en) 2021-05-21
EP3592352A1 (en) 2020-01-15
MX2019010263A (en) 2019-10-09
RU2770039C2 (en) 2022-04-14
RU2019128062A (en) 2021-04-07
CA3048677A1 (en) 2018-09-13
WO2018163085A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
HK1258016A1 (en) Inhalable nicotine formulations, and methods of making and using thereof
IL271736A (en) Nicotine salts and methods of making and using same
HK1254525A1 (en) Therapeutic compositions, combinations, and methods of use
PT3546457T (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
IL261469A (en) Devices for evaporation and inhalation of nicotine
EP3129024A4 (en) Nicotine formulations and methods of making the same
IL268458A (en) Inhalable nicotine formulations, and methods of making and using thereof
GB201513932D0 (en) Keratin treatment formulations and methods
IL261186A (en) Nicotine formulation and aerosols
EP3283151A4 (en) Dry powder inhaler and method of use
IL265870A (en) Nanoparticle formulations and methods of making and using thereof
HK1259372A1 (en) Therapeutic compounds, compositions and methods of use thereof
EP3423040A4 (en) Microneedle particles, compositions, and methods of treatment and delivering a substance of interest
IL258139A (en) Nicotine formulations and methods of making and using the same
PT3527552T (en) Fused tricyclic -amino acid derivative, preparation method therefor, and medical use thereof
PL3373910T3 (en) Echinomycin formulation, method of making and method of use thereof
IL265881A (en) Inhaler and methods of use thereof
RS65120B1 (en) Pharmaceutical formulations and methods of use thereof
IL266132B (en) Pharmaceutical formulations and methods of making the same
EP3562446A4 (en) Nasal implants and methods of use
HK1250205A1 (en) Human milk compositions and methods of making and using same
HK1258765A1 (en) Therapeutic compounds, compositions and methods of use thereof
ZA201807436B (en) Tobacco leaf extract and use thereof for the treatment of tobacco addiction
HK1259196A1 (en) Delayed-release formulations, methods of making and use thereof
HK1226914A1 (en) New non-tobacco cigarette and its preparation